In vitro effect of mopidamol on platelet-subendothelium interaction. 1995

J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.

UI MeSH Term Description Entries
D008297 Male Males
D009012 Mopidamol A phosphodiesterase inhibitor which inhibits platelet aggregation. Formerly used as an antineoplastic. RA-233,Rapenton
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D002450 Cell Communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP. Cell Interaction,Cell-to-Cell Interaction,Cell Communications,Cell Interactions,Cell to Cell Interaction,Cell-to-Cell Interactions,Communication, Cell,Communications, Cell,Interaction, Cell,Interaction, Cell-to-Cell,Interactions, Cell,Interactions, Cell-to-Cell
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
January 1974, Haemostasis,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
January 1979, Microvascular research,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
January 1982, Haemostasis,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
May 1980, Microvascular research,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
July 1995, Thrombosis and haemostasis,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
July 1978, Prostaglandins,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
January 1987, Annals of the New York Academy of Sciences,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
February 1980, The Journal of laboratory and clinical medicine,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
August 1986, Blood,
J P De La Cruz, and M A Villalobos, and R Palacios, and J M Smith-Agreda, and F Sánchez de la Cuesta
May 1975, Microvascular research,
Copied contents to your clipboard!